Cardiac remodeling (cardiac hypertrophy and fibrosis) is a hall mark of heart failure (HF). It can be induced by the abnormal elevation of several endogenous factors including angiotensin II (Ang II), which is generated from its precursor angiotensin I (Ang I) by the action of angiotensin converting enzyme (ACE). The inhibition of this enzyme or the blockade of the Ang II receptors demonstrated a high clinical value against the progression of HF. Ang I and Ang II may also be converted into angiotensin 1-7 (Ang 1-7) and angiotensin 1-9 (Ang 1-9) respectively by the action of angiotensin converting enzyme-2 (ACE2). Both derivatives demonstrated a promising anti-cardiac remodeling activity especially against the detrimental effects of Ang II. This manuscript thoroughly reviews the available in-vitro and in-vivo data on Ang 1-7 and Ang 1-9 in the context of the treatment of HF, and discusses the associated molecular mechanisms and the trials to clinically utilize Ang 1-7 mimetics for the treatment of that disease. This article is protected by copyright. All rights reserved.

Title

Fundamental & Clinical Pharmacology

Publisher

Blackwell Publishing Ltd

Publisher Country

United States of America

Indexing

Thomson Reuters

Impact Factor

2.319

Publication Type

Prtinted only

Volume

32

Year

2018

Pages

14-25